Published in Nature on October 19, 2011
PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell (2013) 3.71
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun (2014) 2.10
Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol (2013) 1.96
A conditional zebrafish MITF mutation reveals MITF levels are critical for melanoma promotion vs. regression in vivo. J Invest Dermatol (2013) 1.74
Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Discov (2014) 1.70
MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells. Proc Natl Acad Sci U S A (2015) 1.68
Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res (2012) 1.49
Detecting endogenous SUMO targets in mammalian cells and tissues. Nat Struct Mol Biol (2013) 1.44
Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med (2013) 1.38
HIF1α and HIF2α independently activate SRC to promote melanoma metastases. J Clin Invest (2013) 1.32
A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet (2013) 1.17
Novel roles for the MiTF/TFE family of transcription factors in organelle biogenesis, nutrient sensing, and energy homeostasis. Cell Mol Life Sci (2014) 1.14
Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. Pigment Cell Melanoma Res (2015) 1.12
The melanocyte lineage in development and disease. Development (2015) 1.11
Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. EMBO Mol Med (2015) 1.11
The metabolic basis of kidney cancer. Semin Cancer Biol (2012) 1.09
The roles of microphthalmia-associated transcription factor and pigmentation in melanoma. Arch Biochem Biophys (2014) 1.05
Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus. Mol Cell Biol (2012) 1.04
Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res (2012) 0.99
Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. J Urol (2013) 0.99
Sumoylation of transcription factor Gcn4 facilitates its Srb10-mediated clearance from promoters in yeast. Genes Dev (2012) 0.98
Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation. Clin Cancer Res (2014) 0.98
Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat Rev Urol (2014) 0.97
MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci (2014) 0.97
SUMOylation regulates the chromatin occupancy and anti-proliferative gene programs of glucocorticoid receptor. Nucleic Acids Res (2013) 0.96
SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression. Nat Commun (2014) 0.96
Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients. J Invest Dermatol (2013) 0.95
SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer. Trends Biochem Sci (2015) 0.95
Hereditary melanoma: Update on syndromes and management: Emerging melanoma cancer complexes and genetic counseling. J Am Acad Dermatol (2016) 0.94
Nephron-sparing surgery for multifocal and hereditary renal tumors. Curr Opin Urol (2014) 0.94
Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking? Lab Invest (2013) 0.92
Replication and predictive value of SNPs associated with melanoma and pigmentation traits in a Southern European case-control study. PLoS One (2013) 0.92
Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype. Oncotarget (2013) 0.92
Sumoylation in gene regulation, human disease, and therapeutic action. F1000Prime Rep (2013) 0.92
Pro-survival role of MITF in melanoma. J Invest Dermatol (2014) 0.91
Restricted leucine zipper dimerization and specificity of DNA recognition of the melanocyte master regulator MITF. Genes Dev (2012) 0.91
SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells. Oncotarget (2014) 0.90
Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Curr Oncol Rep (2012) 0.89
Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. Semin Oncol (2013) 0.89
UV signaling pathways within the skin. J Invest Dermatol (2014) 0.88
Proteome-wide analysis of human disease mutations in short linear motifs: neglected players in cancer? Mol Biosyst (2014) 0.88
CD271 is an imperfect marker for melanoma initiating cells. Oncotarget (2014) 0.86
SUMOylation modulates the transcriptional activity of androgen receptor in a target gene and pathway selective manner. Nucleic Acids Res (2014) 0.86
Wnt signaling potentiates nevogenesis. Proc Natl Acad Sci U S A (2013) 0.86
Molecular characterization of melanoma cases in Denmark suspected of genetic predisposition. PLoS One (2015) 0.85
Genetic counseling in melanoma. Dermatol Ther (2012) 0.85
Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica (Cairo) (2013) 0.85
Gene therapy for advanced melanoma: selective targeting and therapeutic nucleic acids. J Drug Deliv (2013) 0.84
A transcriptional network underlies susceptibility to kidney disease progression. EMBO Mol Med (2012) 0.82
Hypoxia-independent drivers of melanoma angiogenesis. Front Oncol (2015) 0.82
Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia-associated transcription factor signalling pathway. Cell Death Differ (2013) 0.82
MITF mutations associated with pigment deficiency syndromes and melanoma have different effects on protein function. Hum Mol Genet (2013) 0.81
Salmonella VNP20009-mediated RNA interference of ABCB5 moderated chemoresistance of melanoma stem cell and suppressed tumor growth more potently. Oncotarget (2016) 0.81
A gene-expression screen identifies a non-toxic sumoylation inhibitor that mimics SUMO-less human LRH-1 in liver. Elife (2015) 0.81
Precision medicine from the renal cancer genome. Nat Rev Nephrol (2016) 0.80
Multiple primary cancers associated with Merkel cell carcinoma in Queensland, Australia, 1982-2011. J Invest Dermatol (2014) 0.79
Tumor strengths and frailties: Cancer SUMmOns Otto's metabolism. Nat Med (2012) 0.79
The impact of MITF on melanoma development: news from bench and bedside. J Invest Dermatol (2014) 0.79
Evidence for an alternatively spliced MITF exon 2 variant. J Invest Dermatol (2013) 0.79
The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. Lab Invest (2017) 0.78
Chromatin Association of Gcn4 Is Limited by Post-translational Modifications Triggered by its DNA-Binding in Saccharomyces cerevisiae. Genetics (2016) 0.77
Identification of c-MYC SUMOylation by mass spectrometry. PLoS One (2014) 0.77
Role of HIPK2 in kidney fibrosis. Kidney Int Suppl (2011) (2014) 0.77
Melanoma. Shall we move away from the sun and focus more on embryogenesis, body weight and longevity? Med Hypotheses (2013) 0.77
The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response. Oncotarget (2016) 0.77
Update in genetic susceptibility in melanoma. Ann Transl Med (2015) 0.77
Modeling tandem AAG8-MEK inhibition in melanoma cells. Cancer Med (2014) 0.77
MITF E318K's effect on melanoma risk independent of, but modified by, other risk factors. Pigment Cell Melanoma Res (2014) 0.77
Updated field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma: the MelGene database. J Invest Dermatol (2014) 0.76
SUMOylation Confers Posttranslational Stability on NPM-ALK Oncogenic Protein. Neoplasia (2015) 0.76
Metabolic rewiring in melanoma. Oncogene (2016) 0.76
Hormonal Regulation of the Repair of UV Photoproducts in Melanocytes by the Melanocortin Signaling Axis. Photochem Photobiol (2016) 0.76
Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma. Mol Cancer (2017) 0.75
Initial response of renal cell carcinoma to vemurafenib in a patient treated for metastatic melanoma. Can Urol Assoc J (2016) 0.75
SUMO wrestling with Ras. Small GTPases (2016) 0.75
Genetic predisposition to kidney cancer. Semin Oncol (2016) 0.75
SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis. Oncotarget (2016) 0.75
Microphthalmia-associated transcription factor, melanoma, and renal carcinoma: the small ubiquitin-like modifier connection. Pigment Cell Melanoma Res (2011) 0.75
Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev (2017) 0.75
Variants of SCARB1 and VDR Involved in Complex Genetic Interactions May Be Implicated in the Genetic Susceptibility to Clear Cell Renal Cell Carcinoma. Biomed Res Int (2015) 0.75
Cancer genomics: Finding a rare variant. Nat Rev Cancer (2011) 0.75
Activators of G protein signaling in the kidney. J Pharmacol Exp Ther (2015) 0.75
SUMO and the robustness of cancer. Nat Rev Cancer (2017) 0.75
Evaluation of antioxidant and anti-melanogenic activities of different extracts from aerial parts of Nepeta binaludensis Jamzad in murine melanoma B16F10 cells. Iran J Basic Med Sci (2016) 0.75
Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2015) 0.75
Loss of CITED1, an MITF regulator, drives a phenotype switch in vitro and can predict clinical outcome in primary melanoma tumours. PeerJ (2015) 0.75
FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells. Sci Rep (2016) 0.75
Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature? Cancer Biol Ther (2016) 0.75
A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin. Cell Rep (2017) 0.75
Post-translational modification of HINT1 mediates activation of MITF transcriptional activity in human melanoma cells. Oncogene (2017) 0.75
A new POT1 germline mutation-expanding the spectrum of POT1-associated cancers. Fam Cancer (2017) 0.75
A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF. Nat Genet (2017) 0.75
Increased incidence of bladder cancer, lymphoid leukaemia, and myeloma in a cohort of Queensland melanoma families. Fam Cancer (2016) 0.75
Focus on cutaneous and uveal melanoma specificities. Genes Dev (2017) 0.75
A general approach to the design of allosteric, transcription factor-regulated DNAzymes. Chem Sci (2015) 0.75
Finding the missing heritability of complex diseases. Nature (2009) 67.95
Population structure and eigenanalysis. PLoS Genet (2006) 37.21
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Identification of cells initiating human melanomas. Nature (2008) 8.28
Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31
Renal cell carcinoma. Lancet (2009) 6.92
The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol (2010) 5.04
Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol (2009) 4.95
The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med (2004) 4.47
seqMINER: an integrated ChIP-seq data interpretation platform. Nucleic Acids Res (2010) 3.74
Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res (2010) 2.43
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40
Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell Melanoma Res (2009) 2.01
The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol Cell (2006) 1.90
Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol (2008) 1.70
The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet (2001) 1.67
SUMO association with repressor complexes, emerging routes for transcriptional control. Biochim Biophys Acta (2009) 1.67
PTEN regulation by Akt-EGR1-ARF-PTEN axis. EMBO J (2008) 1.58
Regulation of tyrosinase gene expression by cAMP in B16 melanoma cells involves two CATGTG motifs surrounding the TATA box: implication of the microphthalmia gene product. J Cell Biol (1996) 1.57
SUMO under stress. Biochem Soc Trans (2008) 1.47
Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice. Am J Pathol (2006) 1.44
Genomic analysis of the Microphthalmia locus and identification of the MITF-J/Mitf-J isoform. Gene (2005) 1.35
Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr Top Microbiol Immunol (2010) 1.32
Sumoylation modulates transcriptional activity of MITF in a promoter-specific manner. Pigment Cell Res (2005) 1.28
Melanoma epidemiology. Hematol Oncol Clin North Am (2009) 1.21
Cell-specific occupancy of an extended repertoire of CREM and CREB binding loci in male germ cells. BMC Genomics (2010) 1.12
CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1. J Biol Chem (2010) 1.11
Characteristics of the coexistence of melanoma and renal cell carcinoma. Cancer (2010) 1.08
Hypoxia induced CCR7 expression via HIF-1alpha and HIF-2alpha correlates with migration and invasion in lung cancer cells. Cancer Biol Ther (2009) 1.06
Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma. Appl Immunohistochem Mol Morphol (2002) 1.00
Gadd45 proteins as critical signal transducers linking NF-kappaB to MAPK cascades. Curr Cancer Drug Targets (2009) 1.00
A region within the 5'-untranslated region of hypoxia-inducible factor-1alpha mRNA mediates its turnover in lung adenocarcinoma cells. J Biol Chem (2009) 0.99
Reactive oxygen species and molecular regulation of renal oxygenation. Acta Physiol Scand (2003) 0.94
Skin hypoxia: a promoting environmental factor in melanomagenesis. Cell Cycle (2006) 0.92
NF-κB participates in chemokine receptor 7-mediated cell survival in metastatic squamous cell carcinoma of the head and neck. Oncol Rep (2010) 0.91
Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer. Cancer Gene Ther (2010) 0.87
Interleukin-1R-associated kinase 2 is a novel modulator of the transforming growth factor beta signaling cascade. Mol Cancer Res (2010) 0.87
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet (2008) 25.83
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66
International network of cancer genome projects. Nature (2010) 20.35
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet (2007) 14.99
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol (2005) 10.27
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Randomized controlled trial testing the impact of high-protection sunscreens on sun-exposure behavior. Arch Dermatol (2005) 9.42
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med (2009) 8.73
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet (2007) 8.63
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Magnetic domain-wall racetrack memory. Science (2008) 8.24
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet (2009) 7.62
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Mapping complex disease traits with global gene expression. Nat Rev Genet (2009) 7.44
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol (2005) 7.12
Renal cell carcinoma. Lancet (2009) 6.92
The revised Ghent nosology for the Marfan syndrome. J Med Genet (2010) 6.87
Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell (2011) 6.80
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Arginine methylation an emerging regulator of protein function. Mol Cell (2005) 6.49
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Lung cancer susceptibility locus at 5p15.33. Nat Genet (2008) 5.99
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet (2009) 5.62
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet (2005) 5.35
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell (2011) 5.28
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
Global trends of whole-genome duplications revealed by the ciliate Paramecium tetraurelia. Nature (2006) 5.06
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA (2011) 4.84
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet (2012) 4.82
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet (2007) 4.61
The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med (2004) 4.47
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37